All Resources

Our resource hub to discover reports, policy papers and other forms of informative content

Filter by

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.

Learn more | View

PMPRB Notice and Comment Response

Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.

Learn more | View

2021 Federal Pre-Budget Consultation

The industry calls on the federal government to delay implementation of PMPRB regulatory changes until the COVID-19 pandemic has abated. IMC urges the federal government to work with our industry to build a more vibrant life sciences sector – one that enhances patients’ access to innovative medicines and tackles the sector’s critical issues.

Learn more | View

House of Commons Standing Committee on Health (HESA)

The industry campaigns to remove experimental “new economic factors” from regulations – the source of most stakeholder concerns amid 2020 PMPRB changes. IMC encourages government to delay implementation of changes until the COVID-19 pandemic has abated.

Learn more | View


Discover. Learn.

Informative content to keep you up to date on the most pressing issues facing our industry.